0.19
-0.0001(-0.05%)
Currency In USD
| Previous Close | 0.19 |
| Open | 0.18 |
| Day High | 0.23 |
| Day Low | 0.17 |
| 52-Week High | 3.39 |
| 52-Week Low | 0.12 |
| Volume | 121,889 |
| Average Volume | 34,101 |
| Market Cap | 1.58M |
| PE | 0.53 |
| EPS | 0.36 |
| Moving Average 50 Days | 0.17 |
| Moving Average 200 Days | 0.59 |
| Change | -0 |
If you invested $1000 in Bio-Path Holdings, Inc. (BPTH) 10 years ago, it would be worth $0.03 as of June 25, 2025 at a share price of $0.19. Whereas If you bought $1000 worth of Bio-Path Holdings, Inc. (BPTH) shares 5 years ago, it would be worth $1.83 as of June 25, 2025 at a share price of $0.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obe
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Newsfile
Jun 04, 2025 8:34 PM GMT
Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage b
Bio-Path Holdings Provides Clinical and Operational Update
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNA